Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen

Nusinersen is the first approved drug for the treatment of spinal muscular atrophy (SMA). Treatment of SMA with nusinersen is based on a fixed dosing regimen. For other motoneuron diseases, such as amyotrophic lateral sclerosis (ALS), biomarkers are available for clinical diagnostics; however, no su...

Descripción completa

Detalles Bibliográficos
Autores principales: Totzeck, Andreas, Stolte, Benjamin, Kizina, Kathrin, Bolz, Saskia, Schlag, Melina, Thimm, Andreas, Kleinschnitz, Christoph, Hagenacker, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862027/
https://www.ncbi.nlm.nih.gov/pubmed/31671515
http://dx.doi.org/10.3390/ijms20215397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862027/
https://www.ncbi.nlm.nih.gov/pubmed/31671515
http://dx.doi.org/10.3390/ijms20215397

Ejemplares similares